Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial.

[1]  D. Manson,et al.  Correlation of Lung Clearance Index with Hyperpolarized 129Xe Magnetic Resonance Imaging in Pediatric Subjects with Cystic Fibrosis , 2017, American journal of respiratory and critical care medicine.

[2]  J. Pilewski,et al.  55 Lumacaftor/ivacaftor (LUM/IVA) in patients (pts) with cystic fibrosis (CF) and advanced lung disease homozygous for F508del-CFTR: a 24-week open-label study , 2017 .

[3]  M. Rosenfeld,et al.  Lumacaftor/Ivacaftor in Patients Aged 6‐11 Years with Cystic Fibrosis and Homozygous for F508del‐CFTR , 2017, American journal of respiratory and critical care medicine.

[4]  Steve Cunningham,et al.  Detection of early subclinical lung disease in children with cystic fibrosis by lung ventilation imaging with hyperpolarised gas MRI , 2017, Thorax.

[5]  C. Goss,et al.  Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study. , 2017, The Lancet. Respiratory medicine.

[6]  I. Bradbury,et al.  Lung Clearance Index in Adults and Children With Cystic Fibrosis. , 2016, Chest.

[7]  W. T. Harris,et al.  Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study. , 2016, The Lancet. Respiratory medicine.

[8]  Xiaohong Huang,et al.  Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. , 2015, The New England journal of medicine.

[9]  M. Rosenfeld,et al.  Initial evaluation of the Parent Cystic Fibrosis Questionnaire--Revised (CFQ-R) in infants and young children. , 2015, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[10]  S. McColley,et al.  A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. , 2014, The Lancet. Respiratory medicine.

[11]  P. Reix,et al.  Lung clearance index: evidence for use in clinical trials in cystic fibrosis. , 2014, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[12]  P. Lee,et al.  Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial. , 2013, The Lancet. Respiratory medicine.

[13]  Janet Stocks,et al.  Consensus statement for inert gas washout measurement using multiple- and single- breath tests , 2013, European Respiratory Journal.

[14]  N. Derichs.  Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis , 2013, European Respiratory Review.

[15]  P. Latzin,et al.  Multiple-breath washout measurements can be significantly shortened in children , 2012, Thorax.

[16]  P. Negulescu,et al.  Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809 , 2011, Proceedings of the National Academy of Sciences.

[17]  P. Gustafsson,et al.  The effect of dornase alfa on ventilation inhomogeneity in patients with cystic fibrosis , 2011, European Respiratory Journal.

[18]  S. Stanojevic,et al.  Lung Clearance Index and HRCT are complementary markers of lung abnormalities in young children with CF , 2011, Thorax.

[19]  E. Elkin,et al.  Year-to-year changes in lung function in individuals with cystic fibrosis. , 2010, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[20]  F. Ratjen,et al.  Hypertonic saline improves the LCI in paediatric patients with CF with normal lung function , 2010, Thorax.

[21]  Michael D. Ober,et al.  Hepatobiliary Abnormalities and Disease in Cystic Fibrosis: Epidemiology and Outcomes Through Adulthood , 2009, Journal of clinical gastroenterology.

[22]  M. Goldman,et al.  Inert Gas Washout: Theoretical Background and Clinical Utility in Respiratory Disease , 2009, Respiration.

[23]  P. Negulescu,et al.  Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770 , 2009, Proceedings of the National Academy of Sciences.

[24]  A. Quittner,et al.  Determination of the minimal clinically important difference scores for the Cystic Fibrosis Questionnaire-Revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. , 2009, Chest.

[25]  H. Quinton,et al.  Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review. , 2008, Journal of the American Dietetic Association.

[26]  H. Tiddens,et al.  Multiple-breath inert gas washout and spirometry versus structural lung disease in cystic fibrosis , 2007, Thorax.

[27]  J. Clancy,et al.  Detection of cystic fibrosis transmembrane conductance regulator activity in early-phase clinical trials. , 2007, Proceedings of the American Thoracic Society.

[28]  James Rader,et al.  Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. , 2006, American journal of physiology. Lung cellular and molecular physiology.

[29]  L. Duffy,et al.  Use of fecal elastase-1 to classify pancreatic status in patients with cystic fibrosis. , 2004, The Journal of pediatrics.

[30]  J. Walkowiak,et al.  Fecal elastase-1 cut-off levels in the assessment of exocrine pancreatic function in cystic fibrosis. , 2002, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[31]  H. Tiddens.  Detecting early structural lung damage in cystic fibrosis , 2002, Pediatric pulmonology.

[32]  Min Goo Lee,et al.  Aberrant CFTR-dependent HCO-3 transport in mutations associated with cystic fibrosis , 2001, Nature.

[33]  S Grinstein,et al.  Conformational maturation of CFTR but not its mutant counterpart (delta F508) occurs in the endoplasmic reticulum and requires ATP. , 1994, The EMBO journal.

[34]  Pascal Barbry,et al.  Altered chloride ion channel kinetics associated with the ΔF508 cystic fibrosis mutation , 1991, Nature.

[35]  H. A. Berger,et al.  Identification and regulation of the cystic fibrosis transmembrane conductance regulator-generated chloride channel. , 1991, The Journal of clinical investigation.

[36]  J. Gustafson,et al.  Cystic Fibrosis , 2009, Journal of the Iowa Medical Society.